Cintredekin besudotox in treatment of malignant glioma
- PMID: 18476792
- DOI: 10.1517/14712598.8.6.805
Cintredekin besudotox in treatment of malignant glioma
Abstract
Background: Interleukin-13 (IL-13) receptors are overexpressed in glioblastoma multiforme (GBM). The presence of IL-13 binding sites in GBM and their absence in normal brain tissue validates IL-13 receptor as an important target in human GBM.
Objective: This review discusses the bench-to-bedside experience with a recombinant cytotoxin composed of human IL-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR), delivered via convection-enhanced delivery (CED), in GBM treatment.
Methods: The authors review publications regarding the laboratory research and clinical development of IL-13-directed therapies and summarize the future of IL-13-targeted cytotoxin.
Conclusion: The IL-13 receptor remains an important potential target in GBM, and preliminary experience with the IL-13-PE38QQR cytotoxin (also called cintredekin besudotox) has helped to pave the way for study of CED as an important means of drug delivery to malignant gliomas. Ongoing analysis of recently completed clinical trials will determine the future of this agent and its potential therapeutic targets.
Similar articles
-
Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies.Neurosurg Focus. 2006 Apr 15;20(4):E15. Neurosurg Focus. 2006. PMID: 16709020 Clinical Trial.
-
Analysis of target genes induced by IL-13 cytotoxin in human glioblastoma cells.J Neurooncol. 2005 Mar;72(1):35-46. doi: 10.1007/s11060-004-3119-7. J Neurooncol. 2005. PMID: 15803373
-
Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside.J Neurooncol. 2003 Oct;65(1):37-48. doi: 10.1023/a:1026242432647. J Neurooncol. 2003. PMID: 14649884 Review.
-
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.J Clin Oncol. 2007 Mar 1;25(7):837-44. doi: 10.1200/JCO.2006.08.1117. J Clin Oncol. 2007. PMID: 17327604 Clinical Trial.
-
Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy.Technol Cancer Res Treat. 2006 Jun;5(3):239-50. doi: 10.1177/153303460600500307. Technol Cancer Res Treat. 2006. PMID: 16700620 Review.
Cited by
-
Strategies in gene therapy for glioblastoma.Cancers (Basel). 2013 Oct 23;5(4):1271-305. doi: 10.3390/cancers5041271. Cancers (Basel). 2013. PMID: 24202446 Free PMC article.
-
Receptor-Targeted Glial Brain Tumor Therapies.Int J Mol Sci. 2018 Oct 25;19(11):3326. doi: 10.3390/ijms19113326. Int J Mol Sci. 2018. PMID: 30366424 Free PMC article. Review.
-
Current trends in targeted therapies for glioblastoma multiforme.Neurol Res Int. 2012;2012:878425. doi: 10.1155/2012/878425. Epub 2012 Mar 5. Neurol Res Int. 2012. PMID: 22530127 Free PMC article.
-
Production and Evaluation of an Avian IgY Immunotoxin against CD133+ for Treatment of Carcinogenic Stem Cells in Malignant Glioma: IgY Immunotoxin for the Treatment of Glioblastoma.J Oncol. 2019 Jun 2;2019:2563092. doi: 10.1155/2019/2563092. eCollection 2019. J Oncol. 2019. PMID: 31275378 Free PMC article.
-
Immunotherapeutic approaches for glioma.Crit Rev Immunol. 2009;29(1):1-42. doi: 10.1615/critrevimmunol.v29.i1.10. Crit Rev Immunol. 2009. PMID: 19348609 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
